Overview

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

Status:
Completed

Trial end date:
2019-09-20

Target enrollment:

Participant gender:

Summary

This study is being conducted to determine if the uptake of anti-HIV medication, called Genvoya®, at different time-frames, is different at several body sites, including mucosal tissues. This medication might be considered for on-demand PEP regimens in the future.

Phase:

Phase 1

Details

Lead Sponsor:

Emory University

Collaborator:

Centers for Disease Control and Prevention

Treatments:

Anti-Retroviral Agents
Cobicistat
Elvitegravir
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Emtricitabine
Emtricitabine tenofovir alafenamide
Genvoya
Tenofovir